Projektdarstellungen auf der Webseite

Jedes von der Gebert Rüf Stiftung geförderte Projekt wird mit einer Webdarstellung zugänglich gemacht, die über die Kerndaten des Projektes informiert. Mit dieser öffentlichen Darstellung publiziert die Stiftung die erzielten Förderresultate und leistet einen Beitrag zur Kommunikation von Wissenschaft in die Gesellschaft.


LifeMatrix – Biomimetic Solutions for Life


Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.


  • Projekt-Nr: GRS-068/21 
  • Förderbeitrag: CHF 150'000 
  • Bewilligung: 28.10.2021 
  • Dauer: 01.2022 - 02.2024 
  • Handlungsfeld:  InnoBooster, seit 2018



LifeMatrix is active in the fast-growing field of medical biomimetics and has developed a unique bio-engineering technology to grow human replacement tissues in the laboratory as next generation implants for the treatment of cardiovascular diseases. The patented LifeMatrix tissues can be manufactured as heart valves, blood vessels and other cardiovascular structures. When implanted, the patient’s own cells will vitalize and transform the LifeMatrixTM tissue into living heart valves and blood vessels which can grow and regenerate with the patient. The LifeMatrix technology has the objective of overcoming the significant limitations of existing implants.


The LifeMatrixTM Vascular Graft has been developed according to the compliance requirements of the Medical Device Regulation (MDR) and ISO-13485 and has been designed to meet the requirements for several indications in congenital heart surgery. In this regard, the LifeMatrixTM Vascular Graft has been tested extensively in in-vitro bench testing and in-vivo biocompatibility and performance testing which demonstrated clinical grade, long-term, safety and performance in translational GLP animal trials. Within this project we will perform additional in vivo studies to validate the LifeMatrixTM Vascular Graft in other relevant congenital indications (e.g. pulmonary artery reconstruction and right ventricular outflow tract reconstruction). If proven successful, this will allow LifeMatrix to expand the clinical development, strengthen the data for interactions with regulatory authorities, significantly increase the value proposition of the first product in discussions with potential investors and strategic partners and consequently boost the time to market.
To date, the full study protocol for the preclinical assessment of the LifeMatrixTM Vascular Graft has been developed together with a CRO and the LifeMatrixTM Vascular Grafts have been successfully manufactured using LifeMatrix’ proprietary bioengineering process. Following this, the LifeMatrixTM Vascular Grafts were successfully implanted into lambs as per protocol. All implantations were uneventful and the animals made a swift recovery after surgery. All animals completed the follow up uneventfully and the LifeMatrixTM Vascular Grafts showed an unremarkable appearance and performance in the angiography assessments and in the computed tomography evaluation.


Am Projekt beteiligte Personen

Dr. Dr. med. Maximilian Emmert, Co-Founder & Founding CEO

Letzte Aktualisierung dieser Projektdarstellung  25.06.2024